https://orcid.org/0000-0002-4224-4703
Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Aurino M. Kemas, Sonia Youhanna & Volker M. Lauschke. (2022) Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 7:1, pages 39-49.
Read now
Read now
Stuart K Roberts & Ammar Majeed. (2021) A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opinion on Therapeutic Targets 25:10, pages 889-895.
Read now
Read now
Articles from other publishers (30)
Joost Boeckmans, Laurent Sandrin, Christian Knackstedt & Jörn M. Schattenberg. (2023) Liver stiffness as a cornerstone in heart disease risk assessment. Liver International.
Crossref
Crossref
Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan & John Ryan. (2023) Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics.
Crossref
Crossref
Maria Teresa Borrello & Derek Mann. (2022) Chronic liver diseases: From development to novel pharmacological therapies: IUPHAR Review 37. British Journal of Pharmacology 180:22, pages 2880-2897.
Crossref
Crossref
Paul N. Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, Rohit Loomba, Derek A. Mann & Jonathan A. Fallowfield. (2023) Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nature Reviews Gastroenterology & Hepatology 20:10, pages 679-688.
Crossref
Crossref
Emma K McIlwraith, Wenyuan He & Denise D Belsham. (2023) Promise and Perils of MicroRNA Discovery Research: Working Toward Quality Over Quantity. Endocrinology 164:9.
Crossref
Crossref
Samim Ali Mondal, Shivani N. Mann, Carl van der Linden, Roshini Sathiaseelan, Maria Kamal, Snehasis Das, Matthew P. Bubak, Sreemathi Logan, Benjamin F. Miller & Michael B. Stout. (2023) Metabolic benefits of 17α-estradiol in liver are partially mediated by ERβ in male mice. Scientific Reports 13:1.
Crossref
Crossref
Jinyong He, Cuicui Xiao, Cuiping Li, Fan Yang & Cong Du. (2023) Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression. Liver Research 7:2, pages 145-155.
Crossref
Crossref
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, Robim M. Rodrigues, Vera Rogiers & Tamara Vanhaecke. (2023) Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities. Archives of Toxicology 97:6, pages 1825-1827.
Crossref
Crossref
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, Ger H. Koek, Robim M. Rodrigues & Tamara Vanhaecke. (2023)
PNPLA3 I148M
and response to treatment for hepatic steatosis: A systematic review
. Liver International 43:5, pages 975-988.
Crossref
Crossref
Jin Chen, Li Xu, Xue-Qing Zhang, Xue Liu, Zi-Xuan Zhang, Qiu-Mei Zhu, Jian-Yu Liu, Muhammad Omer Iqbal, Ning Ding, Chang-Lun Shao, Mei-Yan Wei & Yu-Chao Gu. (2023) Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis. Marine Life Science & Technology 5:2, pages 196-210.
Crossref
Crossref
Fouzia Gul, Nousheen Parvaiz & Syed Sikander Azam. (2023) Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations. PLOS ONE 18:3, pages e0283743.
Crossref
Crossref
Roberto Cannataro & Erika Cione. (2023) miRNA as Drug: Antagomir and Beyond. Current Pharmaceutical Design 29:6, pages 462-465.
Crossref
Crossref
Manal Sabry Mohamed, Sameh Ghaly, Karim Hamed Azmy & Ghada Abdelrahman Mohamed. (2022) Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. Egyptian Liver Journal 12:1.
Crossref
Crossref
Joshua Levy, Yunrui Lu, Marietta Montivero, Ojas Ramwala, Jason McFadden, Carly Miles, Adam Gilbert Diamond, Ramya Reddy, Ram Reddy, Taylor Hudson, Zarif Azher, Akash Pamal, Sameer Gabbita, Tess Cronin, Abdol Aziz Ould Ismail, Tarushii Goel, Sanjay Jacob, Anish Suvarna, Taein Kim, Edward Zhang, Neha Reddy, Sumanth Ratna, Jason Zavras & Louis Vaickus. (2022) Artificial Intelligence, Bioinformatics, and Pathology. Advances in Molecular Pathology 5:1, pages e25-e52.
Crossref
Crossref
Batuhan Yenilmez, Mark Kelly, Guo-Fang Zhang, Nicole Wetoska, Olga R. Ilkayeva, Kyounghee Min, Leslie Rowland, Chloe DiMarzio, Wentao He, Naideline Raymond, Lawrence Lifshitz, Meixia Pan, Xianlin Han, Jun Xie, Randall H. Friedline, Jason K. Kim, Guangping Gao, Mark A. Herman, Christopher B. Newgard & Michael P. Czech. (2022) Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice. Journal of Biological Chemistry 298:10, pages 102401.
Crossref
Crossref
Scott Q. Siler. (2022) Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. Pharmaceutical Research 39:8, pages 1789-1802.
Crossref
Crossref
Florian Galster, Timo Pöstges, Walburga Hanekamp & Matthias Lehr. (2022)
ω‐(5‐Phenyl‐2
H
‐tetrazol‐2‐yl)alkyl‐substituted hydrazides and related compounds as inhibitors of amine oxidase copper containing 3 (AOC3)
. Archiv der Pharmazie 355:8, pages 2200111.
Crossref
Crossref
Laura E Dichtel, Jose Cordoba-Chacon & Rhonda D Kineman. (2022) Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 107:7, pages 1812-1824.
Crossref
Crossref
Caroline Diener, Andreas Keller & Eckart Meese. (2022) Emerging concepts of miRNA therapeutics: from cells to clinic. Trends in Genetics 38:6, pages 613-626.
Crossref
Crossref
Anshika Jangra, Ashish Kothari, Phulen Sarma, Bikash Medhi, Balram Ji Omar & Karanvir Kaushal. (2022) Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis. Cells 11:9, pages 1500.
Crossref
Crossref
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy & Jean-François Dufour. (2022) PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. International Journal of Molecular Sciences 23:8, pages 4305.
Crossref
Crossref
Enrique de-Madaria, José J Mira, Irene Carrillo, Waqqas Afif, Daphne Ang, Marina Antelo, Steven Bollipo, Antoni Castells, Prabhleen Chahal, Henriette Heinrich, Joanna K Law, Monique E van Leerdam, Sabela Lens, Rahul Pannala, San Hyoung Park, Atoosa Rabiee, Edoardo V Savarino, Vikesh K Singh, John Vargo, Aline Charabaty & Joost P H Drenth. (2022) The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project). The Lancet Gastroenterology & Hepatology.
Crossref
Crossref
Seung Ho Jeon, Eungyeong Jang, Geonha Park, Yeongae Lee, Young Pyo Jang, Kyung-Tae Lee, Kyung-Soo Inn, Jong Kil Lee & Jang-Hoon Lee. (2022) Beneficial Activities of Alisma orientale Extract in a Western Diet-Induced Murine Non-Alcoholic Steatohepatitis and Related Fibrosis Model via Regulation of the Hepatic Adiponectin and Farnesoid X Receptor Pathways. Nutrients 14:3, pages 695.
Crossref
Crossref
Sonia Youhanna, Aurino M. Kemas, Lena Preiss, Yitian Zhou, Joanne X. Shen, Selgin D. Cakal, Francesco S. Paqualini, Sravan K. Goparaju, Reza Zandi Shafagh, Johan Ulrik Lind, Carl M. Sellgren & Volker M. Lauschke. (2022) Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives. Pharmacological Reviews 74:1, pages 141-206.
Crossref
Crossref
Chengyuan Liang, Juan Li, Bin Tian, Lei Tian, Yuzhi Liu, Jingyi Li, Liang Xin, Jun Wang, Chao Fu, Zhenfeng Shi, Juan Xia, Yiting Liang & Kun Wang. (2021) Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Biomedicine & Pharmacotherapy 144, pages 112298.
Crossref
Crossref
Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti & Ariel E. Feldstein. (2021) Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease 41:04, pages 421-434.
Crossref
Crossref
Anja Baumann, Anika Nier, Angélica Hernández-Arriaga, Annette Brandt, Maria J. Lorenzo Pisarello, Cheng J. Jin, Esther Pilar, Amélia Camarinha-Silva, Jörn M. Schattenberg & Ina Bergheim. (2021) Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Scientific Reports 11:1.
Crossref
Crossref
Emily Brown, T. Hydes, A. Hamid & D.J. Cuthbertson. (2021) Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clinical Therapeutics 43:9, pages 1476-1504.
Crossref
Crossref
Amedeo Lonardo, Juan Pablo Arab & Marco Arrese. (2021) Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Advances in Therapy 38:5, pages 2130-2158.
Crossref
Crossref
Seley Gharanei, Kiran Shabir, James E. Brown, Martin O. Weickert, Thomas M. Barber, Ioannis Kyrou & Harpal S. Randeva. (2020) Regulatory microRNAs in Brown, Brite and White Adipose Tissue. Cells 9:11, pages 2489.
Crossref
Crossref